Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PSMA-N064
- Development stage
- Preclinical
- Lead developer
- Radboud University Medical Center
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
PSMA-N064 is a preclinical theranostic, bimodal prostate-specific membrane antigen (PSMA) ligand. It consists of a glutamate-urea-lysine-based PSMA-targeting motif conjugated to the near-infrared (NIR) fluorophore/photosensitizer IRDye700DX and a DOTAGA chelator, which can be radiolabeled with indium-111 (111In). This dual-labeled agent is designed for intraoperative multimodal imaging (using SPECT/CT and near-infrared fluorescence) and targeted photodynamic therapy (tPDT) of prostate cancer. Upon binding to PSMA-expressing tumor cells and subsequent illumination with near-infrared light (690 nm), the IRDye700DX photosensitizer generates reactive oxygen species (ROS), inducing tumor cell apoptosis and DNA double-strand breaks. It has been evaluated in preclinical cell assays, mouse xenograft models, and ex vivo human prostate cancer tissue samples.
- Other names
- 111In-DOTAGA-IRDye700DX-PSMA111In-PSMA-N064DOTAGA-IRDye700DX-PSMADOTAGA-IRDye-700DX-PSMADOTAGA-IRDye 700DX-PSMA[111In]In-DOTAGA-IRDye700DX-PSMA[111In]In-PSMA-N064
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on PSMA-N064.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PSMA-N064.